MORRISVILLE, N.C., March 1, 2012 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) today announced that the Company has modified its sales and marketing effort to focus on the regional U.S. markets of South Florida and North Carolina. Per the plan, promotional efforts will be highly targeted to support existing internal sales efforts, current client sales efforts, and to build brand awareness and grow market share for the Dermacyte brand. This effort is part of an overall program designed to capitalize on the relationships the company has built over the last year in the top markets that have adopted Dermacyte cosmetics into their practices.
In addition, the company plans to introduce new packaging of its flagship products, Dermacyte Concentrate and Dermacyte Oxygenating Eye Complex. The new packaging will incorporate feedback generated from customers regarding product volume, pricing and dispensing.
The new plan was implemented following the termination of its agreements covering distribution of Dermacyte in Europe and Mexico which was reported today on a Form 8-K filed by the company with the Securities and Exchange Commission.
"We have gathered a substantial amount of data in the last few months and have determined that the shotgun approach to promotion is much too costly and challenging in this highly competitive anti-aging skin care market. We have also learned that there is a committed group of customers who love our product and are willing to do all they can to help us succeed so that they are able to continue to purchase our products for themselves and their clients. Over the next few months, we plan to engage local, grassroots efforts to advertise and promote our brand, build credibility and engage our customers in spreading the value and benefits of Dermacyte on our behalf through their own experiences," said Michael Jebsen, President and Chief Financial Officer. "These efforts will be supplemented by continued online sales and promotions."
About Dermacyte skin care products
Dermacyte Concentrate is a highly concentrated oxygen carrier skin care product made with our proprietary oxygen-carrier technology. It gives an "ultra" boost to trouble spots on your face that need it most, such as around your mouth, on your forehead, blemishes, and fine lines around your eyes.
Dermacyte Oxygenating Eye Complex is a lightweight, paraben-free oxygen-carrying serum bolstered by restorative ingredients such as Vitamin C, soothing oat kernel, antioxidants, hydrating sunflower oil and avocado essence. Furthermore, seed extracts from the Pacific and Northeast Meadowfoam plant aid in water loss prevention, a vital component to help overcome the drying effects of winter.
The Dermacyte logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7792
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is developing medical and cosmetic products that efficiently deliver oxygen to tissues in the body. The company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier called Oxycyte® that is currently in clinical and preclinical studies for intravenous delivery for indications such as traumatic brain injury, decompression sickness and stroke. The company is also developing PFC-based oxygen-carrying creams and gels for topical delivery to the skin for dermatologic conditions and potentially wound care. In addition, the company has commercialized its DERMACYTE® line of oxygen-rich skin care products for the anti-aging market.
The Oxygen Biotherapeutics, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7277
Caution Regarding Forward-Looking Statements
This news release contains certain forward-looking statements by the company that involve risks and uncertainties and reflect the company's judgment as of the date of this release. These statements include the Company's ability to execute new sales and marketing program and attain product sales. The forward-looking statements are subject to a number of risks and uncertainties including matters beyond the company's control that could lead to delays in new product introductions and customer acceptance of these new products, and other risks and uncertainties as described in our filings with the Securities and Exchange Commission, including in the current report on Form 10-Q filed on December 15, 2011, and the Form 10-K filed on July 15, 2011. The company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.